Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:27 AM
Ignite Modification Date:
2025-12-25 @ 1:27 AM
NCT ID:
NCT06261294
Eligibility Criteria:
Inclusion Criteria:
* Inclusion
1. Individual who is not mentally impaired, capable to read, understand, and is willing to provide signed and dated informed consent form.
2. Individual is aged 18 years old or above.
3. Individual who is willing to provide information on the given questionnaire. Test group: Individual was diagnosed with pulmonary nodules or masses by low-dose CT (LDCT)/ CT, and evaluated by the physician needed to conduct a biopsy or/ and surgery has been arranged.
Control group: Individual is willing to undergo LDCT or CT scan with 3-5 mm spatial z-axis resolution, pulmonary function examination, X-ray, laboratory blood test, and blood drawing.
4. Control group: Individual has no abnormal finding from LDCT or CT scan with 3-5 mm spatial z-axis resolution and pulmonary function examination(FEV1/FVC Ratio≧70%).
5. Individual did not donate blood or receive blood transfusion within two months before joining the study.
Exclusion Criteria:
* Exclusion
1. Individual who is not suitable for participating as per Investigator's judgement.
2. Individual who has undergone gene therapy or related product within one year prior to enrolling in this study.
3. Individual who is attending another clinical study at the time of enrollment.
4. Individual who is known to be pregnant.
5. Individual who has received a vaccine within two weeks.
6. Individual who has a history of any cancer occurrences other than lung cancer.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06261294
Study Brief:
Protocol Section:
NCT06261294